We are looking forward to the EULAR 2024 Congress in Vienna, Austria. Join us at our Satellite Symposium on Friday, June 14th at 8:15am CEST for an exclusive and interactive presentation from Georg Schett, a pioneer of CAR T cell therapy for the treatment of autoimmune diseases, Carl June, a pioneer of the first CAR T cell therapy approved in oncology, and David J. Chang, MD, MPH, FACR, our Chief Medical Officer who oversaw the development of the only 2 products approved for systemic lupus erythematosus in the United States in over 60 years. You can also find us during the conference at Booths S18 and S19 in Hall B. We look forward to seeing you there! #EULAR2024 #CART #celltherapy #autoimmune
Cabaletta Bio’s Post
More Relevant Posts
-
Consultant Haematologist- Early Phase Trials (The Christie) Honorary Senior Lecturer (University of Manchester)
Great to see this paper published!
A significant day today as inobrodib publishes in Cancer Cell. Press release, with quotes from Tim Somervaille, Emma Searle and Leif Bergsagel, is here: https://lnkd.in/e4hjxH9X The paper confirms inobrodib’s differentiated mechanism of action, displacing p300/CBP from key super-enhancer sites in tumour cells. This impacts the expression of MYC and IRF4, which translates into the clinical activity seen in multiple myeloma (MM) in particular. We believe that displacing and not degrading the targets, is what gives inobrodib its therapeutic window, with some patients remaining on drug over 1.5yrs. Publication: https://lnkd.in/ewZa-i3i Many thanks to our clinical investigators, healthcare teams and collaborative scientists, consultants and CROs. Luciano Nicosia Emma Searle Leif Bergsagel #multiplemyeloma
inobrodib publishes in Cancer Cell
-
Read the latest Oncotarget #announcements and #pressreleases: https://lnkd.in/dd39jgy #openaccess #peerreviewed #oncology #cancer #researchpapers
-
Read the latest Oncotarget #announcements and #pressreleases: https://lnkd.in/dd39jgy #openaccess #peerreviewed #oncology #cancer #researchpapers
In the News | Oncotarget
oncotarget.com
-
Read the latest Oncotarget #announcements and #pressreleases: https://lnkd.in/dd39jgy #openaccess #peerreviewed #oncology #cancer #researchpapers
In the News | Oncotarget
oncotarget.com
-
A significant day today as inobrodib publishes in Cancer Cell. Press release, with quotes from Tim Somervaille, Emma Searle and Leif Bergsagel, is here: https://lnkd.in/e4hjxH9X The paper confirms inobrodib’s differentiated mechanism of action, displacing p300/CBP from key super-enhancer sites in tumour cells. This impacts the expression of MYC and IRF4, which translates into the clinical activity seen in multiple myeloma (MM) in particular. We believe that displacing and not degrading the targets, is what gives inobrodib its therapeutic window, with some patients remaining on drug over 1.5yrs. Publication: https://lnkd.in/ewZa-i3i Many thanks to our clinical investigators, healthcare teams and collaborative scientists, consultants and CROs. Luciano Nicosia Emma Searle Leif Bergsagel #multiplemyeloma
inobrodib publishes in Cancer Cell
-
Please read about the promising results from the first cohort of three patients in our Deltacel-01 Phase 1 clinical trial at Beverly Hills Cancer Center. "Consistency in safety, tolerability, and disease stability is of paramount importance at this stage of testing, and the data thus far bolster our confidence in Deltacel's potential as a transformative treatment," stated Pietro Bersani, Chief Executive Officer of Kiromic BioPharma. “The findings are especially promising considering the robustness of response in the absence of brain metastasis, and the notable reduction in tumor size for the second and the first patient, respectively." #cartcelltherapy #celltherapy #patientsfirst https://lnkd.in/eVycTBzU
-
Read the latest Oncotarget #announcements and #pressreleases: https://lnkd.in/dd39jgy #openaccess #peerreviewed #oncology #cancer #researchpapers
In the News | Oncotarget
oncotarget.com
-
Read the latest Oncotarget #announcements and #pressreleases: https://lnkd.in/dd39jgy #openaccess #peerreviewed #oncology #cancer #researchpapers
In the News | Oncotarget
oncotarget.com
-
Tomorrow is Glioblastoma Awareness Day. According to the Brain Tumour Foundation of Canada, the incidence of glioblastoma (GB), also known as glioblastoma multiforme, is 4 per 100,000 people in Canada. There's growing evidence that cannabis and its derivatives may be effective in treating cancer, including glioblastoma multiforme. Visit our learning centre for up-to-date research! https://buff.ly/3NVmDDK #glioblastomaawarenessday #medicalcannabis
-
-
Read the latest Oncotarget #announcements and #pressreleases: https://lnkd.in/dd39jgy #openaccess #peerreviewed #oncology #cancer #researchpapers
In the News | Oncotarget
oncotarget.com
